RoActemra 162 mg solution for injection in pre-filled syringe., Humira 80 mg solution for injection in pre-filled pen
APHP200007
Phase 2 small_molecule active
Quick answer
RoActemra 162 mg solution for injection in pre-filled syringe., Humira 80 mg solution for injection in pre-filled pen for Severe uveitis of Behçet’s disease is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Severe uveitis of Behçet’s disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active